Clinical Trials

40 enrolled

Biliary Tract Neoplasms

NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

35 enrolled

Cholangiocarcinoma

NCT07007182 2026-05-01

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07555678 2026-04-29

Chase

241 enrolled

Anus Neoplasms

NCT06964568 2026-04-17

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Phase 3 Recruiting

452 enrolled

Esophageal Neoplasms

NCT07519486 2026-04-15

INS-ESCC-CT

118 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Locally Advanced Rectal Cancer

NCT07486492 2026-03-20

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

10 enrolled

Colorectal Cancer Metastatic

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT05621707 2026-02-02

RICE

50 enrolled

Phase 1/2 Active not recruiting

Esophageal Neoplasms

NCT06710847 2026-02-02

SYLVER

14 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Carcinoma, Hepatocellular

NCT07339488 2026-01-14

ILDR-03

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT07279077 2025-12-26

MODIFI-L

38 enrolled

Colonic Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

144 enrolled

Carcinoma, Hepatocellular

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT06248554 2025-12-02

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

200 enrolled

Carcinoma, Hepatocellular

NCT06154538 2025-11-28

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

170 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Locally Advanced Colorectal Carcinoma

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1 Terminated

17 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06496373 2025-11-17

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

20 enrolled

Pancreatic Neoplasms

NCT07230301 2025-11-17

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

20 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Pancreatic Cancer Metastatic

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT07154108 2025-09-04

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

40 enrolled

GastrointestinalHead & Neck

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms

NCT07149181 2025-08-29

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

Phase 4 Not yet recruiting

1,000 enrolled

Phase 4 Not yet recruiting

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07132528 2025-08-20

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

1,000 enrolled

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

32 enrolled

Carcinoma, Hepatocellular

NCT06196671 2025-08-07

PTCA199-8

30 enrolled

Pancreatic Neoplasms

NCT06958432 2025-08-07

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Phase 2/3 Recruiting

430 enrolled

Phase NA Not yet recruiting

Rectal Neoplasms

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

98 enrolled

Esophageal Squamous Cell Carcinoma

NCT07064668 2025-07-15

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

300 enrolled

Carcinoma, Hepatocellular

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Phase 1 Not yet recruiting

Locally Advanced Rectal Cancer (LARC)

NCT07034118 2025-06-24

Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study

23 enrolled

Phase 1 Active not recruiting

Esophageal Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06991907 2025-05-28

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

Phase NA Completed

80 enrolled

Carcinoma, Hepatocellular

NCT06957977 2025-05-06

A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer

42 enrolled

Stomach Neoplasms

NCT06685887 2025-04-11

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

34 enrolled

Stomach Neoplasms

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05491616 2025-02-13

SANO-3

77 enrolled

Esophageal Neoplasms

NCT05497453 2025-02-03

MYCHELANGELO I

Phase 1/2 Terminated

24 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05937438 2025-01-29

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Phase 1/2 Recruiting

70 enrolled

Esophageal Neoplasms

NCT06622031 2025-01-13

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

42 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT06708650 2024-11-27

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

50 enrolled

Carcinoma, Hepatocellular

NCT04294784 2024-11-04

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Phase 2 Terminated

58 enrolled

Stomach Neoplasms

NCT04230759 2024-09-19

RADIANCE

180 enrolled